Agonist polypeptide of receptor for zot and zonulin

Abstract

Agonist polypeptide of a receptor protein has been identified. The agonist can be used to facilitate drug and antigen absorption. Suitable routes of administration include oral, nasal, transdermal, and intravenous. Pharmaceutical formulations may comprise a therapeutic agent or an immunogenic agent in combination with the agonist polypeptide.

1 - 80 . (canceled) 
     
     
         81 . A peptide comprising the amino acid sequence of SEQ ID NO: 4, wherein said peptide is less than 10 amino acid residues in length. 
     
     
         82 . The peptide of  claim 81 , wherein said peptide consists of the amino acid sequence of SEQ ID NO: 4. 
     
     
         83 . The peptide of  claim 81 , wherein said peptide does not comprise residues 294-298 of SEQ ID NO: 1. 
     
     
         84 . The peptide of  claim 81 , wherein said peptide is less than 8 amino acid residues in length. 
     
     
         85 . A pharmaceutical composition comprising the peptide of  claim 81 . 
     
     
         86 . A composition comprising the peptide of  claim 81 , wherein said composition is selected from the group consisting of: an oral dosage composition; a nasal dosage composition; an intravenous dosage composition; and a skin dosage composition. 
     
     
         87 . A pharmaceutical composition comprising the peptide of  claim 82 . 
     
     
         88 . A composition comprising the peptide of  claim 82 , wherein said composition is selected from the group consisting of: an oral dosage composition; a nasal dosage composition; an intravenous dosage composition; and a skin dosage composition. 
     
     
         89 . A peptide comprising an amino acid sequence selected from the group consisting of: Xaa 1  Cys Ile Gly Arg Leu (SEQ ID NO: 7); Phe Xaa 2  Ile Gly Arg Leu (SEQ ID NO: 8); Phe Cys Xaa 3  Gly Arg Leu (SEQ ID NO: 9); Phe Cys Ile Xaa 4  Arg Leu (SEQ ID NO: 10); Phe Cys Ile Gly Xaa 5  Leu (SEQ ID NO: 11); and Phe Cys Ile Gly Arg Xaa 6  (SEQ ID NO: 12), wherein said peptide is less than 100 amino acid residues in length, and further wherein Xaa 1  is selected from the group consisting of Ala, Val, Leu, Ile, Pro, Trp, Tyr, and Met; Xaa 2  is selected from the group consisting of Gly, Ser, Thr, Tyr, Asn, and Gln; Xaa 3  is selected from the group consisting of Ala, Val, Leu, Ile, Pro, Trp, and Met; Xaa 4  is selected from the group consisting of Gly, Ser, Thr, Tyr, Asn, Ala, and Gln; Xaa 5  is selected from the group consisting of Lys and His; and Xaa 6  is selected from the group consisting of Ala, Val, Leu, Ile, Pro, Trp, and Met. 
     
     
         90 . The peptide of  claim 89 , wherein said peptide consists of six amino acid residues. 
     
     
         91 . A pharmaceutical composition comprising the peptide of  claim 89 . 
     
     
         92 . A composition comprising the peptide of  claim 89 , wherein said composition is selected from the group consisting of: an oral dosage composition; a nasal dosage composition; an intravenous dosage composition; and a skin dosage composition. 
     
     
         93 . A pharmaceutical composition comprising the peptide of  claim 90 . 
     
     
         94 . A composition comprising the peptide of  claim 90 , wherein said composition is selected from the group consisting of: an oral dosage composition; a nasal dosage composition; an intravenous dosage composition; and a skin dosage composition. 
     
     
         95 . A peptide comprising an amino acid sequence selected from the group consisting of: Xaa 1  Xaa 2  Ile Gly Arg Leu (SEQ ID NO: 13); Xaa 1  Cys Xaa 3  Gly Arg Leu (SEQ ID NO: 14); Xaa 1  Cys Ile Xaa 4  Arg Leu (SEQ ID NO: 15); Xaa 1  Cys Ile Gly Xaa 5  Leu (SEQ ID NO: 16); Xaa 1  Cys Ile Gly Arg Xaa 6  (SEQ ID NO: 17); Phe Xaa 2  Xaa 3  Gly Arg Leu (SEQ ID NO: 18); Phe Xaa 2  Ile Xaa 4  Arg Leu (SEQ ID NO: 19); Phe Xaa 2  Ile Gly Xaa 5  Leu (SEQ ID NO: 20); Phe Xaa 2  Ile Gly Arg Xaa 6  (SEQ ID NO: 21); Phe Cys Xaa 3  Xaa 4  Arg Leu (SEQ ID NO: 22); Phe Cys Xaa 3  Gly Xaa 5  Leu (SEQ ID NO: 23); Phe Cys Xaa 3  Gly Arg Xaa 6  (SEQ ID NO: 24); Phe Cys Ile Xaa 4  Xaa 5  Leu (SEQ ID NO: 25); Phe Cys Ile Xaa 4  Arg Xaa 6  (SEQ ID NO: 26); and Phe Cys Ile Gly Xaa 5  Xaa 6  (SEQ ID NO: 27), wherein said peptide is less than 100 amino acid residues in length, and further wherein Xaa 1  is selected from the group consisting of Ala, Val, Leu, Ile, Pro, Trp, Tyr, and Met; Xaa 2  is selected from the group consisting of Gly, Ser, Thr, Tyr, Asn, and Gln; Xaa 3  is selected from the group consisting of Ala, Val, Leu, Ile, Pro, Trp, and Met; Xaa 4  is selected from the group consisting of Gly, Ser, Thr, Tyr, Asn, Ala, and Gln; Xaa 5  is selected from the group consisting of Lys and His; and Xaa 6  is selected from the group consisting of Ala, Val, Leu, Ile, Pro, Trp, and Met. 
     
     
         96 . The peptide of  claim 95 , wherein said peptide consists of six amino acid residues. 
     
     
         97 . A pharmaceutical composition comprising the peptide of  claim 95 . 
     
     
         98 . A composition comprising the peptide of  claim 95 , wherein said composition is selected from the group consisting of: an oral dosage composition; a nasal dosage composition; an intravenous dosage composition; and a skin dosage composition. 
     
     
         99 . A pharmaceutical composition comprising the peptide of  claim 96 . 
     
     
         100 . A composition comprising the peptide of  claim 95 , wherein said composition is selected from the group consisting of: an oral dosage composition; a nasal dosage composition; an intravenous dosage composition; and a skin dosage composition.